In participants with BRAF V600-mutant unresectable or metastatic melanoma or other advanced solid tumors, encorafenib steady-state Cmax and AUClast were decreased in presence of steady-state modafinil by approximately 20% and 24%, respectively, indicating that moderate CYP3A4 inducers will not cause a clinically significant reduction in encorafenib exposures. Here, BRAF is linked to metastatic melanoma.